Atomoxetine in the Treatment of Binge Eating Disorder

Phase 4

Completed

• Conditions: Binge-eating Disorder

• Registration Number: NCT00327834
• Lead Sponsor: Lindner Center of HOPE

Brief Summary

The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-05
• Study First Submitted: 2006-05-17
• Study First Submitted QC: 2006-05-17
• Study First Posted: 2006-05-19
• Primary Completion: 2007-03
• Study Completion: 2007-03
• Status Verified: 2011-06
• Last Update Submitted: 2011-06-21
• Last Update Posted: 2011-06-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Subjects will meet the DSM-IV criteria for a diagnosis of binge-eating disorder for at least the last 6 months
• In addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization

Exclusion Criteria

• Have concurrent symptoms of bulimia nervosa or anorexia nervosa
• Women who are pregnant, lactating, or of child bearing potential who are not using adequate contraceptive measures
• Patients who are displaying clinically significant suicidality or homicidality

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

University of Cincinnati Medical Center; 🇺🇸 Cincinnati, Ohio, United States